The Leishmaniasis Treatment Market is estimated to be valued at US$ 69.4 Mn in 2023 and is expected to exhibit a CAGR of 17% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Leishmaniasis is a tropical disease caused by Leishmania parasites. It is transmitted to humans through the bite of infected female sand flies. The disease manifests in three main forms: cutaneous, mucocutaneous, and visceral leishmaniasis. Treatment depends on the form of the disease. Available treatment options include pentavalent antimonials, amphotericin B, miltefosine and paromomycin. However, these drugs have toxic side effects and resistance is a major issue. Therefore, there is a high need for safe and effective drugs for leishmaniasis treatment.

Market key trends:
One of the key trends in the leishmaniasis treatment market is increasing research and development efforts towards the development of novel therapeutics. Several pharmaceutical companies are engaged in developing drugs with novel mechanisms of action and better safety profiles. For instance, drug candidates like fostamatinib (R788), DB829 and ERG100 are in clinical trials for leishmaniasis treatment. Fostamatinib is a novel spleen tyrosine kinase inhibitor being developed by Rigel Pharmaceuticals. DB829 and ERG100 are RNA interference based drug candidates in Phase 1 and Phase 2 trials respectively being developed by Daiichi Sankyo and Esperance Pharmaceuticals. Such ongoing drug development efforts are expected to bring new treatment options and drive the market growth during the forecast period.

Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate due to high R&D costs and regulations associated with drug development in the leishmaniasis treatment market. However, opportunities exist for specialty drugs.
Bargaining power of buyers: The bargaining power of buyers is moderate due to the availability of alternative treatment options. However, the urgent need for novel drugs drives prices.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the specialized nature of inputs required for drug development. This encourages collaboration.
Threat of new substitutes: The threat of new substitutes is high given the rising drug development in the field.
Competitive rivalry: is intense as major players compete for market share.

SWOT Analysis
Strengths: Availability of pipeline drugs and government support for R&D.
Weaknesses: High costs associated with drug development and differing disease burdens globally. Limited treatment options in developing nations.
Opportunities: Untapped growth potential in developing countries and scope for combination therapies.
Threats: Stringent regulations and pricing pressures. Emergence of drug-resistant strains.

Key Takeaways
The Global Leishmaniasis Treatment Market Size is expected to witness high growth, exhibiting CAGR of 17% over the forecast period, due to increasing disease prevalence across tropical and subtropical regions. The market size for 2023 is US$ 69.4 Mn.

Regionally, North America dominates the market currently due to high awareness and healthcare spending. However, South Asia and Latin America are likely to emerge as the fastest growing markets due to the increasing burden of visceral leishmaniasis in countries such as India, Bangladesh and Brazil.

Key players operating in the Leishmaniasis Treatment market are Merck, iCo Therapeutics, AEterna Zentaris, AEterna Zentaris AG, Eurofins Advinus, Pieris Pharmaceuticals, Dafra Pharma. Major players are focusing on new drug developments and product launches to consolidate their market position. For instance, Merck has an extensive pipeline of drugs to treat leishmaniasis while AEterna Zentaris is developing an oral formulation of paromomycin.

For More Insights, Read: https://www.newswirestats.com/leishmaniasis-treatment-market-demand-growth-and-regional-outlook-by-2030/